Adverum Biotechnologies Inc
$ 4.36
0.00%
09 Dec - close price
- Market Cap 96,258,000 USD
- Current Price $ 4.36
- High / Low $ 4.36 / 4.36
- Stock P/E N/A
- Book Value -2.53
- EPS -8.57
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.77 %
- ROE -4.18 %
- 52 Week High 5.75
- 52 Week Low 1.78
About
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company based in Redwood City, California, specializing in innovative therapeutic solutions for rare diseases and ophthalmic disorders. The company is advancing a robust pipeline of gene therapy candidates utilizing its proprietary adeno-associated virus (AAV) technologies, designed to address significant unmet medical needs in the field. With a commitment to developing transformative treatments, Adverum is poised to improve patient outcomes and strengthen its foothold in the dynamic gene therapy sector.
Analyst Target Price
$4.88
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-11 | 2025-05-07 | 2025-03-17 | 2024-11-07 | 2024-08-12 | 2024-05-09 | 2024-03-18 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -2.03 | -2.34 | -1.9586 | -1.96 | -1.3 | -0.89 | -1.5 | -2.3 | -0.33 | -0.31 | -0.29 | -0.33 |
| Estimated EPS | -1.7 | -2.284 | -1.974 | -1.385 | -1.31 | -1.47 | -1.4 | -3.37 | -0.32 | -0.33 | -0.32 | -0.36 |
| Surprise | -0.33 | -0.056 | 0.0154 | -0.575 | 0.01 | 0.58 | -0.1 | 1.07 | -0.01 | 0.02 | 0.03 | 0.03 |
| Surprise Percentage | -19.4118% | -2.4518% | 0.7801% | -41.5162% | 0.7634% | 39.4558% | -7.1429% | 31.7507% | -3.125% | 6.0606% | 9.375% | 8.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADVM
2025-12-13 20:09:15
Adverum Biotechnologies (NASDAQ:ADVM) has been downgraded to a "strong sell" by Wall Street Zen, adding to several recent broker downgrades, although MarketBeat's consensus remains a "Hold" with a target price of $10.50. The company recently missed EPS expectations, reporting -$2.03 against an expected -$1.80, and has seen notable insider trading activity. Despite a major shareholder selling over 500,000 shares, the CEO purchased 117,614 shares, and institutional investors collectively own 48.17% of the stock.
2025-12-09 22:09:26
Eli Lilly and Company has successfully completed its tender offer to acquire Adverum Biotechnologies, Inc., with approximately 64% of Adverum’s shares validly tendered. The acquisition, which concluded on December 9, 2025, aims to expand Lilly's gene therapy capabilities, particularly in treating age-related conditions like vision loss. Lilly looks forward to integrating Adverum's expertise to develop innovative genetic medicines.
2025-12-09 22:08:29
Adverum Biotechnologies' CEO, Laurent Fischer, recently purchased shares totaling over $550,000 in two separate transactions in early December. These buys significantly increased his stake in the company. Despite an elevated trading volume and a market capitalization of approximately $96.3 million, the company recently missed its quarterly EPS consensus, and analysts currently have a "Hold" rating on the stock with a $10.50 price target.
2025-12-09 08:28:00
Eli Lilly and Company announced the successful expiration and completion of its tender offer to acquire Adverum Biotechnologies, Inc. Lilly's direct wholly-owned subsidiary, Flying Tigers Acquisition Corporation, purchased approximately 64% of Adverum's outstanding shares at $3.56 per share plus a contingent value right. This acquisition aims to expand gene therapy's potential for age-related conditions, including vision loss, and welcomes Adverum colleagues to Lilly.
2025-12-09 07:28:00
Eli Lilly and Company announced the successful completion of a tender offer by its subsidiary, Flying Tigers Acquisition Corporation, to acquire all outstanding shares of Adverum Biotechnologies, Inc. Approximately 64% of Adverum's shares were validly tendered and accepted for payment, with the acquisition expected to close on December 9, 2025. This acquisition aims to expand gene therapy's potential for age-related conditions like vision loss, welcoming Adverum colleagues to Lilly to further develop innovative genetic medicines.
2025-12-09 04:09:05
Adverum Biotechnologies (NASDAQ:ADVM) COO Peter Soparkar recently purchased 50,000 shares of the company's stock for $211,000, increasing his stake by 165.62%. Despite this insider buying, the company's fundamentals remain weak with a reported ($2.03) EPS for the last quarter and a consensus analyst rating of "Hold." The stock briefly traded up 2.3% on the day of the disclosure.
